

Effects of Supplements on Sexual Dysfunctions Caused by Antidepressants

Daniel Gomes*

Department of Psychiatry, Medical University of Warsaw, Poland

Introduction

Antidepressant-induced SD between men and women differs significantly, according to information collected in recent decades. Accordingly, decreased sexual desire and arousal as well as challenges in eliciting satisfaction are the side effects most commonly reported by women. In contrast, males who used serotonergic medications frequently complained of delayed ejaculation, while those who took TCAs and iMAO mostly complained of reduced orgasmic performance. For the management of AISD, to more have been proposed. First, doctors may think about waiting a few months for spontaneous symptom remission to see if these side effects are recoverable [1]. The use of phosphodiesterase-5 inhibitors, which are typically successful in the treatment of AD-induced erectile dysfunction and anorgasmia in men, is another option that clinicians have. Clear guidelines for the management of these side effects are still missing, despite the clinical approach indicated above and the suggested remedies. In addition, the widespread use of Advertisements for a variety of mental diseases, the sheer numbers of people who take them, as well as the possible negative effects on treatment compliance including long-term outcomes all argue for an expansion of the AISD therapy options.

In this situation, complementary and alternative medicine, a large and diverse collection of treatment techniques that include natural supplements, plant-based phytochemicals, and nutrient-based nutraceuticals, appears to improve human health and may have a positive impact on a wide range of disorders. Nutraceuticals, which are defined as "natural substances such as food or a component of them, a vitamin, a mineral, or a herb with therapeutic effects for human health," have received attention recently. They can be used alone or as an addition to regular care.

There is currently a dearth of a systematic review on how these nutraceuticals affect AISD, though. We conducted a systematic literature assessment of the information already available on the use of nutraceuticals for the treatment of AISD in older adults in light of the expanding clinical and scientific interest in this field of research [2].

Discussion

To the best of our knowledge, this research is the first comprehensive analysis of RCTs looking at the impact of nutraceuticals on adult-onset autism spectrum disorder. All trial participants demonstrated improved sexual function, and the majority of the patients were female. Due to the equivocal outcomes of the in vivo replication, prior findings in animal research have not been validated, but the large increase in libido supports these findings. The relatively

limited sample size and the considerable positive placebo effect recorded [3]. Patients typically lamented about delayed orgasm, arousal issues, and low libido. 16 individuals qualified for just an intention to treat analysis, and 10 subjects finished the trial. Improvement level seemed to be dose-related. The 17-item Hamilton Depression Rating Scale scores for the ITT recipients of the high-dose were similarly shown to have significantly improved.

Additionally, distinct sex-related effects were seen; these results were likely attributed to the fact that male and female psychophysiological sexuality circuits are not equivalent. When analysing the reaction to nutritional supplements, it's also important to take into consideration some physiological factors and personal weaknesses. In reality, it is not considered out that these elements, either separately or together, may have contributed to the paucity of evidence for the positive benefits. The availability of an augmentation technique that enhances SD has the potential to significantly enhance patient compliance and quality of life. However, we should take into account the possibility that patients may complain of SD due to their untreated or just partially treated depressive disorder as well as a side effect of the AD treatment. In truth, it is well known how important it is to assess sexual function prior to and after AD therapy in order to learn whether there has been an improvement due to the reduction of depressive symptoms or an AISD. Although prior results in animal research have not been verified as a consequence of the equivocal outcomes from the in vivo replication on female patients, the substantial improvement in libido supports those findings [4].

The postmenopausal women subgroup was responsible for a strong link between change in sex hormones with improvement in sexually functions, according to the scientists. A positive effect might be hypothesized regarding Maca on menopausal symptoms and hormone levels in women. Accordingly, a previous study on postmenopausal women treated with Maca showed a significant decrease in FSH level. Therefore, in women, it might be hypothesized that Maca may have an indirect androgenic response through a negative feedback pathway involving the LH/FSH, whereas the increased production of androgens might explain the improvement in sexual functioning. Taken together, these findings may shed light on the mechanisms of Maca, although previous findings in men failed to prove direct androgenic effects. Maca may have a beneficial impact on female menopause symptoms and hormone levels, according to certain theories. As a result, a prior study on postmenopausal women receiving Maca treatment revealed a significantly lower FSH level. In light of this, it's indeed possible to speculate that Maca may have an indirect androgen receptor effect on women via an LH/FSH-related negative feedback mechanism whereas the increased synthesis of androgens may account for the improvement in sexual performance [5]. Together, these findings may give light on the processes of recommended doses, despite the fact that earlier research in men did not succeed in demonstrating a direct androgenic effects.

Conclusion

Nutraceuticals' role in AISD has been thoroughly reviewed. There is still conflicting evidence regardless of the fact that Macha Root, SAME, Rosa hollow cylindrical, and Lavender may have positive effects. Future RCTs should use larger samples and take into account any potential confounding variables, like individual vulnerability and depressed status.

*Address for Correspondence: Daniel Gomes, Department of Psychiatry, Medical University of Warsaw, Poland; E-mail: gomesd43@gmail.com

Copyright: © 2022 Gomes D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Date of submission: 03 September, 2022, Manuscript No. cdp-22-76109; Editor Assigned: 09 September 2022, PreQC No: P-76109; Reviewed: 22 September, 2022, QC No. Q-76109; Revised: 26 September, 2022, Manuscript No. R-76109; Published: 29 September, 2022, DOI: 10.37421/2572-0791.2022.8.29.

Conflict of Interest

None.

References

1. Brent, David, Graham Emslie, Greg Clarke and Karen Dineen Wagner, et al. "Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial." *JAMA* 299 (2008): 901-913.
2. Copeland, William E., Lilly Shanahan, E. Jane Costello, and Adrian Angold. "Childhood and adolescent psychiatric disorders as predictors of young adult disorders." *Arch Gen Psychiatry* 66 (2009): 764-772.
3. Bolton, Paul, Judith Bass, Theresa Betancourt and Liesbeth Speelman, et al. "Interventions for depression symptoms among adolescent survivors of war and displacement in northern Uganda: A randomized controlled trial." *JAMA* 298 (2007):519-527.
4. Bridge, Jeffrey A., Boris Birmaher, Satish Iyengar and Rémy P. Barbe. "Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder." *Am J Psychiatry* 166 (2009): 42-49.
5. Angold, Adrian, E.J. Costello, A. Erkanli and C.M. Worthman. "Pubertal changes in hormone levels and depression in girls." *Psychol Med* 29 (1999): 1043-1053.

How to cite this article: Gomes, Daniel. "Effects of Supplements on Sexual Dysfunctions Caused by Antidepressants." *Clin Depress* 8 (2022):29.